Rifabutin

Routes
Oral (PO)
Half-Life (t½)
PO: 36h
Formula
C46H62N4O11
Molecular Weight
847.01 g/mol
PubChem CID
135415564
Aliases
Mycobutin

Pharmacological Mechanism

Spiropiperidyl rifamycin — narrower CYP3A4 induction than rifampin, used in HIV+TB co-treatment where rifampin would crater PI levels. Still meaningfully induces CYP3A4 (~40% AUC reduction of co-administered substrates).

Half-Life & Elimination Curve (PO: 36h)

100%50%25%12.5%0%0h0×t½36h1×t½3d2×t½4.5d3×t½6d4×t½7.5d5×t½0×t½ (0h): 100% remaining (~72.9 µg/L)1×t½ (36h): 50% remaining (~36.4 µg/L)2×t½ (3d): 25% remaining (~18.2 µg/L)3×t½ (4.5d): 12.5% remaining (~9.11 µg/L)4×t½ (6d): 6.3% remaining (~4.55 µg/L)5×t½ (7.5d): 3.1% remaining (~2.28 µg/L)
Plasma (PO)t½ Decay (36h)
  • 0×t½0h100% (72.9 µg/L)
  • 1×t½36h50% (36.4 µg/L)
  • 2×t½3d25% (18.2 µg/L)
  • 3×t½4.5d12.5% (9.11 µg/L)
  • 4×t½6d6.3% (4.55 µg/L)
  • 5×t½7.5d3.1% (2.28 µg/L)
Elimination t½36h (PO)
Rate Constant (ke)0.0193 h⁻¹
Time to Peak (Tmax)5.28h
Est. Peak (Cmax)72.9 µg/L
Clearance (CL)11.5 L/h
97% Washout (5×t½)7.5d

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Interactions

Chemical Structure & Identifiers

References